Document:

Judgment Sharing Agreement

 Exhibit 10.3 
 SUBJECT TO FED. R. EVID. 408 
 JUDGMENT SHARING AGREEMENT
BETWEEN 
 MASTERCARD AND VISA IN THE DISCOVER LITIGATION 
 This Judgment Sharing Agreement (the “Agreement”) between MasterCard and Visa in the Discover Litigation is made, as of July 29, 2008 (the
“Effective Date”), between Visa Inc. and MasterCard Incorporated (the “Parties,” and each a “Party”). The Parties seek through this Agreement to provide for the apportionment of certain costs and liabilities, as
described herein, which they may incur jointly and/or severally in the event of an adverse judgment, or settlement or settlements, in Discover Financial Services v. Visa U.S.A. Inc., Case No. 04-CV-07844 (S.D.N.Y.) (the
“Litigation”). In consideration of the mutual covenants and agreements contained herein, the Parties hereby agree as follows: 
 Definitions 
  

	A.	“Affiliate” shall mean any corporation, firm, limited liability company, partnership or other entity that directly or indirectly Controls or is Controlled by or is under
common Control with a Person, including any such entity that is Controlled by a Person after the Effective Date. 

  

	B.	“Claim” shall mean any and all manner of claims, demands, actions, causes of action, suits, damages, liabilities, judgments, debts, claims over, accounts, warranties,
liens, costs or expenses whatsoever, whether based in contract law, tort law, equity, statute, or regulation that are known as of the Effective Date. A Claim shall not include any payments due or other obligations owed under contracts or agreements
that do not pertain to the Litigation and which continue to remain in effect after the Effective Date. “Claims” shall mean more than one Claim. 

  

	C.	“Control” (including the terms “Controls,” “Controlled by” or “under common Control with”) shall mean ownership, directly or through one or
more Affiliates, in the case of a corporation, of fifty percent (50%) or more of the shares of the stock entitled to vote for the election of directors (or such lesser percentage which is the maximum allowed to be owned by a foreign entity in a
particular 

  

 1 

 SUBJECT TO FED. R. EVID. 408 
 jurisdiction), or, in the case of any other entity, fifty percent (50%) or more of the equity interests (or such lesser percentage which is the
maximum allowed to be owned by a foreign entity in a particular jurisdiction) and having equal or more control of the board of directors or equivalent governing body of such entity. 
  

	D.	“Discover” means Discover Financial Services, DFS Services LLC, and Discover Bank. 

  

	E.	“Final Judgment” means that portion of a judgment for monetary relief of any kind, including any award of compensatory, treble, or other damages and interest, court costs,
attorneys’ fees, or expenses, entered on Claims in the Litigation by a court on the basis of trial, summary judgment, judgment as a matter of law, or any other basis, which (a) is immediately enforceable and has not been stayed pending
appeal or (b) becomes final after exhaustion of all appeals or other judicial review or expiration of the time to obtain further judicial review. For purposes of this Agreement, the Final Judgment shall be calculated prior to offset or
reduction on account of settlement payments by a party that does not comply with the provisions of paragraph 4 of this Agreement. 

  

	F.	“MasterCard” refers collectively to MasterCard International Incorporated, MasterCard Incorporated, currently doing business as MasterCard Worldwide, and their Affiliates.

  

	G.	“MasterCard Member” shall mean a Person authorized by MasterCard or its Affiliates to be an issuer or acquirer of Payment Cards with any MasterCard brand or any Person
otherwise admitted to membership under the rules of MasterCard. 

  

	H.	“Payment Cards” shall mean credit cards, debit cards, charge cards, prepaid cards, stored value cards, commercial cards, virtual cards, and other payment transaction
products or devices (including those that do not utilize a tangible card). 

  

	I.	“Person” shall mean an individual, corporation, partnership, limited liability company, estate, trust, common or collective fund, association, private foundation, joint
stock company or other entity. 

  

	J.	“Visa” refers collectively to Visa Inc., Visa U.S.A. Inc., Visa International Service Association, and their Affiliates. 

  

	K.	“Visa Europe” shall mean Visa Europe Limited, Visa Europe Services Inc., and their Affiliates. 

  

	L.	“Visa Member” shall mean a Person authorized by Visa or its Affiliates or by Visa Europe to be an issuer or acquirer of Payment Cards with any Visa brand or any Person
otherwise admitted to membership under the rules of Visa or Visa Europe. 

  

	M.	“Visa U.S.A.” refers to Visa U.S.A. Inc. 

  

	N.	“Visa International” refers to Visa International Service Association. 

  

 2 

 SUBJECT TO FED. R. EVID. 408 
 Agreement 
  

	1.	Sharing of Final Judgment. Subject to paragraph 4 below, each Party shall pay the portion of any Final Judgment enforced against any Party as set forth in this paragraph:

  

	 	(a)	Visa shall pay the “Visa Share,” which shall equal the sum of: 

  

	 	(i)	**** 

  

	 	(ii)	**** 

  

	 	(iii)	**** 

  

	 	(b)	MasterCard shall pay the “MasterCard Share,” which shall equal the sum of: 

  

	 	(i)	**** 

  

	 	(ii)	**** 

  

	 	(iii)	**** 

  

	2.	Repayment of Overpayments. If a Party makes judgment payments to Discover in excess of its share of a Final Judgment as set forth in paragraph 1 (an “Excess
Payment,” and such Party an “Overpaying Party”), then the other Party will reimburse the Overpaying Party to the extent of its Excess Payment. The Overpaying Party’s right to reimbursement for its Excess Payment shall be
enforceable in a proceeding for contribution or indemnity. A Party may make demand for payment pursuant to this paragraph at any time after making an Excess Payment. A Party shall pay any proper claim for contribution, indemnity, or reimbursement
under this paragraph within 21 days of demand. 

  

	3.	Settlement. In the event the Parties reach a mutually acceptable, aggregate settlement with Discover, each Party shall pay the portion of any such settlement pursuant to the
allocation provided in paragraph 1. Any Party may settle claims asserted against it in the Litigation at any time at its sole discretion. 

  

	4.	Relief from Judgment Sharing Obligation. A party that settles claims asserted against it in the Litigation shall have no obligation to share in a Final Judgment pursuant to
this Agreement if and only if the conditions in sub-paragraphs (a)-(c) immediately below are satisfied: 

  

	 	(a)	**** 

  

 3 

 SUBJECT TO FED. R. EVID. 408 
  

	 	(b)	In the case of a settlement by Visa: 

  

	 	(i)	**** 

  

	 	(ii)	**** 

  

	 	(c)	In the case of a settlement by MasterCard: 

  

	 	(i)	**** 

  

	 	(ii)	**** 

  

	 	(d)	Any dispute regarding the value of non-cash consideration paid by a Party as consideration for a settlement shall be resolved pursuant to the provisions of paragraph 12.

  

	 	(e)	Overturned, Modified, or New Judgment. If (a) a Final Judgment is modified at any time after it becomes a Final Judgment and, as so modified (the “Modified
Judgment”), becomes final after exhaustion of all appeals or other judicial review or expiration of the time to obtain further judicial review, or (b) after a Final Judgment is vacated or overturned, a new Final Judgment (“New
Judgment”) is subsequently entered, then the sharing obligations of each Party shall be recalculated under the terms of this Agreement to reflect the Modified Judgment or New Judgment, as applicable. 

  

	5.	Repayment. If Discover receives payment from a Party based on a claim asserted in the Litigation and Discover is no longer entitled to some or all of that payment as a result
of the reversal, vacatur, or modification of a Final Judgment (an “Overpayment”), and if a Party later succeeds in recovering the Overpayment in whole or in part, such recovery (including any interest recovered) shall be taken into account
for purposes of determining the sharing, indemnity, and contribution obligations arising under this Agreement. Unless and until an Overpayment is recovered by a Party, however, the Overpayment shall be treated as a payment towards the satisfaction
of a Final Judgment for purposes of this Agreement, provided that the Overpayment was made in satisfaction or partial satisfaction of what was, at the time the payment was made, a Final Judgment as defined by this Agreement.

  

	6.	No Admission of Liability. Nothing contained herein is intended to be, nor shall be deemed to be, an admission of any liability to anyone or an admission of the existence of
facts upon which liability could be based other than to the Parties pursuant to the terms of this Agreement. 

  

 4 

 SUBJECT TO FED. R. EVID. 408 
  

	7.	No Third-Party Beneficiaries. This Agreement is made and shall be binding on and inure solely to the benefit of the Parties and their respective successors or permitted
assigns but otherwise confers no rights or defenses upon any non-Party. A Party may not assign any of its obligations under this Agreement to another person or entity without the written consent of each other Party. Subject to the foregoing, each
Party shall require any entity(ies) that, as a result of any merger, purchase of assets, reorganization or other transaction, acquires or succeeds to all or substantially all of the business or assets of such Party to assume the obligations of such
Party under this Agreement pursuant to a binding and effective written assumption agreement, with reasonable advance written notice of the assumption agreement to the other Party. 

  

	8.	Governing Law. This Agreement shall be governed by and interpreted in accordance with the laws of the State of Delaware, without regard to its conflicts of law principles.
All Parties hereby agree that this Agreement is consistent with public policy. 

  

	9.	Confidentiality. Each Party has independently determined its securities law obligations arising from this Agreement. Taking into account those obligations, the Parties agree
that to the extent there is a disclosure of the Agreement, each Party will take reasonable steps to ensure confidential treatment of paragraphs 1(a)(i)-(iii), 1(b)(i)-(iii), as well as paragraphs 4(a), 4(b)(i)-(ii) and 4(c)(i)-(ii) of the
Agreement from Securities and Exchange Commission or any other party to which disclosure is made. Each Party agrees to give the other Party reasonable notice in the event it decides to take any action that will disclose paragraphs 1(a)(i)-(iii),
1(b)(i)-(iii), or any part of paragraphs 4(a), 4(b)(i)-(ii) and 4(c)(i)-(ii) of this Agreement, or that otherwise is inconsistent with the second sentence of this paragraph 9. Further, the Parties agree that the terms and conditions of
this Agreement shall remain confidential with the following exceptions: (1) the Parties may disclose the terms and conditions of this Agreement to the extent such disclosure is required by law or regulation or any rule or requirement of any
stock exchange, self-regulatory agency (including the National Association of Securities Dealers) or rating agency; (2) the Parties may disclose the terms and conditions of this Agreement to the extent such disclosure is required by court order
or rule; (3) the Parties may disclose the terms and conditions of this Agreement to the extent such disclosure is necessary to the Parties’ financial and legal advisors and other third parties that are involved in asset review, audit, or
other due diligence, provided reasonable precautions are taken to ensure the continued confidentiality of the information disclosed; (4) the Parties may disclose the terms and conditions of this Agreement to the extent disclosure is necessary
to enforce or comply with the terms of this Agreement, provided reasonable precautions are taken to ensure the continued confidentiality of the information disclosed; (5) Visa may disclose the terms and conditions of this Agreement to
Visa’s Members to the extent required to obtain the consent of such Members required by the Visa rules, provided that reasonable precautions are taken to ensure continued confidential treatment of the information disclosed; and

  

 5 

 SUBJECT TO FED. R. EVID. 408 
 (6) the Parties may disclose the terms and conditions of this Agreement pursuant to written agreement of the Parties. Except with regard to disclosure
under exception (3), in the event of disclosure under this paragraph, the disclosing party must provide reasonable advance written notice to the other party as soon as practicable. In the event either Party determines that any disclosure of the
terms and conditions of this Agreement is required by law or regulation or any rule or requirement of any stock exchange, self-regulatory agency (including the National Association of Securities Dealers) or rating agency, the other Party also may
disclose the terms and conditions of the Agreement to the same extent. Further, in the event of disclosure under exception (2), the disclosing party must provide reasonable advance written notice to the other party as soon as practicable after
receiving a request or demand for such disclosure, and will not make such disclosure until the other party has been given a reasonable opportunity to oppose or object to such production. For the avoidance of any doubt, nothing herein shall preclude
any Party from disclosing either (i) that the Visa Share of any Final Judgment or Settlement is larger, based primarily on relevant volumes, or (ii) that the Visa Share of any Final Judgment or Settlement is the substantial majority, based
primarily on relevant volumes. Further, nothing herein shall preclude any Party from disclosing this Agreement, or any provision of this Agreement, to the extent (a) the Securities and Exchange Commission or other regulatory authority has
denied a request for confidential treatment (provided reasonable efforts are made to persuade the Securities and Exchange Commission or other regulatory authority, and provided the other Party is notified in advance of the pending disclosure), or
(b) to the extent it has otherwise become public through no violation of this Agreement. 
  

	10.	Interpretation. For purposes of interpretation, this Agreement shall be deemed to have been drafted by the Parties equally and no ambiguity shall be resolved against any
Party by virtue of their participation in the drafting of this Agreement. 

  

	11.	Assignability. No Party may assign all or any of its rights or obligations under this Agreement without the express written consent of the other Party. This Agreement shall
apply to and bind the Parties and their respective successors in interest, including any entity succeeding to or acquiring a controlling interest in any significant, wholly-owned business division of a Party or a significant portion of the
Party’s assets. 

  

	12.	Dispute Resolution. Resolution of disputes between the Parties shall be subject to the following dispute resolution procedures. 

  

	 	(a)	All disputes between the Parties concerning the interpretation and enforcement of this Agreement shall be subject to a dispute resolution format that includes: (i) written
notice setting forth a brief description of the claim; (ii) an opportunity to cure within 30 days of receipt of the notice; and (iii) binding arbitration in the event that such resolution does not occur within the time frame set forth
above. Such arbitration will be 

  

 6 

 SUBJECT TO FED. R. EVID. 408 
 in accordance with the Center for Public Resources (“CPR”) Rules for Non-Administered
Arbitration in effect on the date of this Agreement. Such arbitration shall be conducted, as follows: (i) presumptively, there will be limited
discovery; (ii) presumptively, there will be a hearing of no more than three (3) days; and (iii) presumptively, the binding arbitration shall be concluded within twenty (20) business days from the latter of the completion of
discovery or selection of the three arbitrators, provided that upon good cause shown, the arbitrators may allow for additional time not to exceed forty (40) business days from the latter of the completion of discovery or selection of the three
arbitrators. 
  

	 	(b)	Selection and Number of Arbitrators. A panel of three arbitrators shall conduct the arbitration proceeding. The arbitrators shall be selected as follows: (i) the Party
initiating the arbitration proceeding shall have absolute discretion to select one of the three arbitrators, provided such selection is proper pursuant to the CPR Rules for Non-Administered Arbitration, within three business days of the demand for
arbitration; (ii) the Party responding to the arbitration proceeding shall have absolute discretion to select one arbitrator, provided such selection is proper pursuant to the CPR Rules for Non-Administered Arbitration, within five business
days of the selection of the first arbitrator; and (iii) the two arbitrators so selected shall jointly select a third arbitrator (the “Neutral”) that formerly served as a Federal judge or has substantial experience in complex
arbitration proceedings, and in either case preferably possesses experience in the electronic payment industry, within five business days of the selection of the second arbitrator. If the two Party arbitrators selected under (i) and
(ii) above cannot agree on a Neutral within the time provided, the Parties shall each exchange lists of three qualified candidates and any candidate appearing on both lists shall be selected as the Neutral, with this process continuing up to
three times until a candidate appears on both lists. If this process does not succeed with the selection of a Neutral within an additional five business days, the Parties shall request that the CPR select a Neutral possessing the above
qualifications. 

  

	 	(c)	Venue. The Party responding to the arbitration proceeding shall have the right to select either San Francisco, California or New York, New York as the location of the
arbitration proceeding, unless otherwise agreed by the Parties. The arbitrators need not be located in or near the selected venue so long as they are willing to travel to the venue to conduct the arbitration. 

  

	 	(d)	Applicable Rules. The CPR Rules for Non-Administered Arbitration shall govern any arbitration proceeding. In the event of any conflict or inconsistency between the CPR Rules
for Non-Administered Arbitration and the provisions of this Agreement, the provisions of this Agreement shall govern. 

  

 7 

 SUBJECT TO FED. R. EVID. 408 
  

	13.	Counterparts. This Agreement may be executed in counterparts with the same force and effect as if executed in one complete and original document. 

  

	14.	Severability. If any paragraph or clause of this Agreement is found to be illegal or invalid or unenforceable for any reason, it shall be deemed to be modified to the minimum
extent necessary to cure such illegality, invalidity, or unenforceability and the remaining paragraphs and clauses of this Agreement will remain in full force and effect. In the event any Party claims an invalidated provision was material to the
consideration for this Agreement, the question of materiality and modification of the offending provision shall be subject to the dispute resolution provision of paragraph 12 of this Agreement. 

  

	15.	Approvals. Each Party affirms for the other Party that no further approvals of or votes on this Agreement are required. 

  

			
	 Visa Inc., Visa U.S.A. Inc., and Visa
 International Service Association

		
	By:	 	 /s/ Joshua R. Floum

		 	Joshua R. Floum
		 	General Counsel and Corporate Secretary
		 	Visa Inc.
		 	Dated: July 29, 2008
	
	MasterCard International Incorporated and MasterCard Incorporated
		
	By:	 	 /s/ Noah J. Hanft

		 	Noah J. Hanft
		 	General Counsel, Chief Franchise Officer & Corporate Secretary
		 	MasterCard Incorporated
		 	Dated: July 29, 2008

  

 8Non-Competition Agreement

 Exhibit 10.2 
 NON-COMPETITION AGREEMENT 
 THIS NON-COMPETITION AGREEMENT (this “Agreement”)
is entered into as of July 6, 2008, by and between Fresenius SE, a societas europaea organized under the laws of Germany (the “Company”), and Dr. Patrick Soon-Shiong (“Shareholder”), a shareholder
of APP Pharmaceuticals, Inc., a Delaware corporation (“APP”). 
 RECITALS 
 A. APP is engaged in the business of developing, in-licensing, manufacturing, selling, marketing and distributing APP Generic Pharmaceutical Products (as
defined below) (such business, the “Business”). 
 B. Shareholder is a significant stockholder and chairman of APP, and
until recently, Shareholder was an executive officer of APP as well. Accordingly, Shareholder has acquired confidential and proprietary information relating to the Business and operations of APP. 
 C. Shareholder’s covenant not to compete, as reflected in this Agreement, is an essential inducement to the Company to enter into the transactions
described in the Agreement and Plan of Merger dated as of July 6, 2008 (the “Merger Agreement”), among the Company, Fresenius Kabi Pharmaceuticals Holding, LLC, a Delaware limited liability company and an indirect, wholly-owned
subsidiary of the Company (“Holdco”), Fresenius Kabi Pharmaceuticals, LLC, a Delaware limited liability company and a direct, wholly-owned subsidiary of Holdco, and APP (the transactions contemplated by the Merger Agreement are
referred to hereinafter as the “Merger”). Capitalized terms not defined herein shall have the definition ascribed to such term in the Merger Agreement. 
 D. It is anticipated that Shareholder will continue his association with APP and the Company following the consummation of the Merger as a consultant and advisor to the Company. 
 E. Shareholder, directly or indirectly, holds a substantial number of the issued and outstanding shares of stock of APP for which he will receive
valuable consideration as part of the Merger, and therefore has a material economic interest in the consummation of the Merger. 
 F. In
order to protect the goodwill related to the Business, the Shareholder has agreed to the restrictive covenants set forth in this Agreement. 
 AGREEMENT 
 NOW, THEREFORE, in consideration of the foregoing and to induce the Company to consummate the
transactions contemplated by the Merger Agreement and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Shareholder hereby covenants and agrees as follows: 
 1. Effective Date. This Agreement shall be effective as of the Closing. This Agreement shall be void and have no force or effect if the Merger
Agreement is terminated prior to the Effective Time or the Merger is otherwise not consummated. 

 2. Non-Competition. 
 (a) Shareholder and the Company agree that due to the nature of Shareholder’s past and continuing association with APP, Shareholder has received and is knowledgeable about, and will continue to receive,
confidential and proprietary information relating to the business and operations and the relationships with employees, customers and suppliers of APP and its Affiliates. Shareholder acknowledges that such information is of extreme importance to the
business of APP and the Company, and will be of extreme importance to APP and the Company after the Merger. 
 (b) Shareholder and the
Company further agree that the market for APP Generic Pharmaceutical Products is intensely competitive and that APP engages in the Business throughout the United States and Canada. 
 (c) During the period which shall commence at the time of the Closing and shall terminate four (4) years from the Effective Date (the
“Restricted Period”), Shareholder shall not, without prior written consent of the Company, with such permission to be given in the Company’s sole and absolute discretion, directly or indirectly (including without limitation,
through any Affiliate (as defined below) of Shareholder), own, manage, operate, control or otherwise engage or participate in, or be connected to, as an owner, partner, principal, creditor, salesperson, advisor, member of the board of directors of,
employee of, or consultant to, any company, business, venture or any division, group or other subset of a company, business or venture that engages in any substantive part of the Business in which APP is engaged at the time of the Merger (each a
“Competitor”) within the Restricted Area (as defined below) (such activities, the “Restricted Activities”); provided, however, that the following shall not constitute “Restricted Activities”
and this section shall not prohibit Shareholder from directly or indirectly (including without limitation, through any Affiliate (as defined below) of Shareholder) (i) owning, managing, operating, controlling or otherwise engaging in,
participating in or being connected to developing, in-licensing, manufacturing, selling, marketing and/or distributing biosimilar, follow-on biologics, generic biologic products or oxaliplatin or enoxaparin or dalteparin, provided that Shareholder
may only conduct such activities with respect to oxaliplatin in the manner currently being conducted by Shareholder in connection with the acquisition of Shimoda Biotech (Pty) Ltd. and its subsidiary, (ii) contract manufacturing (and the
related activities necessary to perform contract manufacturing) of APP Generic Pharmaceutical Products by Abraxis BioScience, Inc. in the manner currently being conducted in the Abraxis BioScience, Inc. facility in Phoenix, Arizona,
(iii) contract manufacturing (and the related activities necessary to perform contract manufacturing) by Abraxis BioScience, Inc. or one or more of its Subsidiaries of APP Generic Pharmaceutical Products upon the consent of the Company, such
consent not to be unreasonably withheld, (iv) developing (and related in-licensing and manufacturing) APP Generic Pharmaceutical Products upon the consent of the Company, such consent not to be unreasonably withheld, so long as such products
are not sold, marketed and/or distributed within the Restricted Area during the Restricted Period and (v) serving as a director, consultant or advisor of APP or the Company or any Affiliate of the Company. 
 (d) Notwithstanding the foregoing provisions of Section 2(c) and the restrictions set forth therein, Shareholder or his Affiliates may: (i) own
(A) securities in any Competitor that is a publicly held corporation, but only to the extent that Shareholder does not own, of record or beneficially, more than 3% of the outstanding beneficial ownership of any such Competitor and
(B) securities in any Competitor, provided that the Shareholder acquired such securities as the result of a sale or other distribution of Abraxis BioScience, Inc. to any Person and provided further that the Shareholder does not own, of record
or beneficially, more than 15% of the outstanding beneficial ownership of any such Competitor and (ii) acquire and hold control of any Person or business (or an interest in any Person or business) that at all times when held by the Shareholder
or his Affiliates (based on the then-preceding fiscal year) derives less than 15% of its revenues from the Restricted Activities. 
  

 2 

 (e) “APP Generic Pharmaceutical Product” means the products listed on Schedule
2(e) hereto, in any dosage and in the form (intravenous and nonintravenous) as marketed, developed or planned to be developed by APP at the time of the Merger; for the avoidance of doubt, with respect to oral generic products, APP Generic
Pharmaceutical Products shall only include those oral generic products listed on Schedule 2(e) in their current formulation. 
 (f)
“Affiliate” as used herein, means, with respect to any Person or entity, any Person or entity directly or indirectly controlling, controlled by or under common control with such other Person or entity, and in respect of any
individual, members of his or her immediate family, any trust for the benefit of such individual and/or members of his or her immediate family and any other entity in which such individual or any members of his or her immediate family separately or
collectively hold (directly or indirectly) a majority of the outstanding equity interests or of which they are trustees. 
 (g)
“Immediate Family” as used herein, means an individual’s spouse, children, parents and anyone else who shares the individual’s home. 
 (h) “Restricted Area” as used herein, means each county or similar political subdivision of each State of the United States of America and each province of Canada. 
 3. Non-solicitation of Company Employees. During the Restricted Period, Shareholder shall not, directly or indirectly (including without
limitation, through any Affiliate of Shareholder), and without the prior written consent of the Company, solicit or attempt to solicit, any person who is at the time of such solicitation or attempted solicitation an employee of APP or any controlled
Affiliate of APP to leave the employ of APP or any controlled Affiliate of APP; provided, however, this section shall not prohibit (a) Shareholder or any of his Affiliates from soliciting or hiring any person who responds to a
general advertisement or solicitation not specifically directed at employees of APP or any Affiliate of APP or (b) efforts by recruiting or employment agencies, provided that such recruiting or employment agencies are not directed to target
such employees. 
 4. Non-solicitation of Customers; Non-Disparagement. During the Restricted Period, Shareholder shall not, directly
or indirectly (including without limitation, through any Affiliate of Shareholder) (a) solicit, induce or attempt to induce any Customer (as defined below) of APP, the Company or any Affiliate of the Company to cease doing business in whole or
in part with APP, the Company or any respective Affiliate of the Company with respect to the Business in the Restricted Area; (b) attempt to limit or interfere in any material respect with any business agreement existing between APP or the
Company and/or Affiliates of the Company and any third party, of which Shareholder is aware or put on notice; or (c) make any public oral or written statements that disparage the business reputation of APP or the Company (or its management
team); provided, however, that this clause 4 shall not prohibit the Shareholder or his Affiliates from exercising and enforcing their rights under the CVR Indenture or any other agreement between the Shareholder and the Company, APP or
one of their Affiliates. “Customer” as used herein means any customer or client of APP, the Company or any Affiliate of the Company about which Shareholder has or had access to confidential information, primarily by virtue of
Shareholder’s association with APP, the Company or any Affiliate of the Company. 
 5. Non-solicitation of Suppliers. During the
Restricted Period, Shareholder shall not, directly or indirectly (including without limitation, through any Affiliate of Shareholder) solicit, induce or attempt to induce any Supplier (as defined below) of APP, the Company or any Affiliate of the
Company to cease doing business in whole or in part with APP, the Company or any respective Affiliate of the Company with respect to the Business in the Restricted Area. “Supplier” as used herein means any raw material or finished
dosage form supplier of APP, the Company or any Affiliate of the Company about 

  

 3 

 
which Shareholder has or had access to confidential information, primarily by virtue of Shareholder’s association with APP, the Company or any Affiliate
of the Company. 
 6. Confidentiality. Shareholder covenants that he will not, at any time during the period from the Effective Time
through the end of the 12-month period immediately following the Restricted Period, directly or indirectly, use for his own account, or disclose to any person, firm or corporation, other than in the performance of services to APP or the Company, any
Confidential Information (as hereinafter defined). As used herein, “Confidential Information” means non-public information about APP and/or the Company of any kind, nature or description, including, but not limited to, any proprietary
knowledge, trade secrets, data, formulae, employee data, and client and customer lists and all documents, papers, resumes and records (including computer records) which is disclosed to or otherwise known to the Shareholder as a direct or indirect
consequence of his association with APP and his association with the Company in the context of and subsequent to the Merger. Shareholder acknowledges that such Confidential Information is specialized, unique in nature and of great value to APP
and/or the Company and that such information gives APP and/or the Company a competitive advantage in the Business. Confidential Information shall not include information that is (a) the product of Shareholder’s general knowledge,
education, training and/or experience obtained prior to his employment with APP or without the benefit of any non-public information of APP or the Company; (b) generally known and/or used by persons with the general knowledge, education,
training and/or experience comparable to that of Shareholder; (c) common knowledge in the industry; or (d) otherwise legally in the public domain through no fault of Shareholder or the wrongdoing of any other party. 
 7. Injunctive Relief; Damages; Limitation of Liability. The parties agree that the remedy at law for any breach of this Agreement is and will be
inadequate, and in the event of a breach or threatened breach by Shareholder of the provisions of Sections 2, 3, 4, 5 and/or 6 of this Agreement, the Company shall be entitled to seek an injunction restraining Shareholder from the conduct which
would constitute a breach of this Agreement. Nothing herein contained shall be construed as prohibiting the Company from pursuing any other remedies available to it for such breach or threatened breach, including, without limitation, the recovery of
damages from Shareholder. Although the parties hereto may seek to recover damages, no party to this Agreement shall under any circumstances be held liable whether in contract, in tort, under any warranty or any other theory of liability, for any
indirect, incidental, special, consequential or punitive damages, including but not limited to, loss of revenue, loss of opportunity, business disruption or other pecuniary loss arising out of this Agreement and/or related services, even if they
have been advised of the possibility of such damages. 
 8. Reasonableness and Enforceability of Covenants. 
 (a) The parties expressly agree that the character, duration and geographical scope of this Agreement are reasonable in light of the circumstances as they
exist on the date upon which this Agreement has been executed, including, but not limited to, Shareholder’s material economic interest in the Merger, his position of confidence and trust as an executive employee of APP and his anticipated
ongoing association with APP and the Company as a consultant. 
 (b) If any court of competent jurisdiction determines that any of the
covenants and agreements contained herein, or any part thereof, is unenforceable because of the character, duration or geographic scope of such provision, such court shall have the power to reduce the duration or scope of such provision, as the case
may be, and, in its reduced form, such provision shall then be enforceable to the maximum extent permitted by applicable law. 
 (c)
Shareholder acknowledges that (i) as part of the Merger, the Company will be vested with the goodwill of, and will directly or indirectly carry on, the Business that had been conducted 

  

 4 

 
by APP prior to the Merger, (ii) the restrictive covenants and the other agreements contained herein are an essential part of this Agreement, and
(iii) the Merger is designed and intended to qualify as a sale (or other disposition) by Shareholder of all of Shareholder’s interests in APP within the meaning of section 16601 of the Business and Professions Code of California (the
“BPCC”). 
 (d) Shareholder further represents, warrants and agrees that (i) Shareholder has been fully advised by, or has had
the opportunity to be advised by, counsel in connection with the negotiation, preparation, execution and delivery of this Agreement and the transactions contemplated by this Agreement and the Merger Agreement; and (ii) Shareholder has read
section 16601 of the BPCC and agrees that section 16601 of the BPCC applies in the context of the Merger. Accordingly, Shareholder agrees to be bound by the restrictive covenants and the other agreements contained in this Agreement to the maximum
extent permitted by law, it being the intent and spirit of the parties that the restrictive covenants and the other agreements contained herein shall be valid and enforceable in all respects, and, subject to the terms and conditions of this
Agreement. 
 9. Severability. If any of the provisions of this Agreement shall otherwise contravene or be invalid under the laws of
any state, country or other jurisdiction where this Agreement is applicable but for such contravention or invalidity, such contravention or invalidity shall not invalidate all of the provisions of this Agreement but rather it shall be construed,
insofar as the laws of that state, country or jurisdiction are concerned, as not containing the provision or provisions contravening or invalid under the laws of that state or jurisdiction, and the rights and obligations created hereby shall be
construed and enforced accordingly. 
 10. Construction. This Agreement shall be construed and enforced in accordance with and
governed by the laws of the State of California, without regard to principles of conflicts or choice of laws. The parties hereby irrevocably and unconditionally consent to submit to the jurisdiction of the federal courts located in the county of Los
Angeles or any California state courts located in the county of Los Angeles (and if appropriate, appellate courts therefrom) in connection with any suit, action or proceeding arising out of or related to this Agreement (and agree not to commence any
suit, action or proceeding relating thereto except in those courts), waive any defense or objection they may have or hereafter have relating to the laying of venue to any suit, action or proceeding in any such courts, and agree not to plead or claim
that any suit, action or proceeding brought therein has been brought in an inconvenient forum. 
 11. Amendments and Waivers. This
Agreement may be modified only by a written instrument duly executed by each party hereto. No breach of any covenant, agreement, warranty or representation shall be deemed waived unless expressly waived in writing by the party who might assert such
breach. No waiver of any right hereunder shall operate as a waiver of any other right or of the same or a similar right on another occasion. 
 12. Entire Agreement. This Agreement, together with the Merger Agreement and the ancillary documents executed in connection therewith, contains the entire understanding of the parties relating to the subject matter hereof, supersedes
all prior and contemporaneous agreements and understandings relating to the subject matter hereof and shall not be amended except by a written instrument signed by each of the parties hereto. In the event of any conflict or inconsistency between
this Agreement and any other agreement between Shareholder and APP and/or the Company, or any APP or Company policy, with respect to business activities, confidential information or other matters addressed herein, including any agreement entered
into in the future, the terms of this Agreement shall govern unless such other agreement provides to the contrary by specific reference to this Agreement. 
  

 5 

 13. Counterparts. This Agreement may be executed by the parties in separate counterparts, each of
which, when so executed and delivered, shall be an original, but all of which, when taken as a whole, shall constitute one and the same instrument. 
 14. Section Headings. The headings of each Section, subsection or other subdivision of this Agreement are for reference only and shall not limit or control the meaning thereof. 
 15. Assignment. Neither this Agreement nor any right, remedy, obligation or liability arising hereunder or by reason hereof nor any of the
documents executed in connection herewith may be assigned by any party without the consent of the other parties. 
 16. Further
Assurances. From time to time, at the Company’s request and without further consideration, Shareholder shall execute and deliver such additional documents and take all such further action as reasonably requested by the Company to be
necessary or desirable to make effective, in the most expeditious manner possible, the terms of this Agreement. 
 17. Notices. All
notices and other communications hereunder shall be in writing and shall be deemed given if delivered personally or two business days after being mailed by registered or certified mail (return receipt requested) to the parties at the following
addresses (or at such other address for a party as shall be specified by like notice): 
 (a) if to the Company: 

Fresenius SE 
 61346 Bad Homburg v.d.H. 
 Germany 
 Facsimile: +49 6172 608 5017 
 Telephone: +49 6172 608 2333 
 Attn: General Counsel 
 with a copy to: 
 Skadden, Arps, Slate, Meagher & Flom (UK) LLP 
 40 Bank Street 
 Canary Wharf 
 London E14 5DS 
 Facsimile: +44 (0) 207 519 7070 
 Telephone: +44 (0) 207 519 7000 
 Attn: Scott V. Simpson, Esq. 
          Michal
Berkner, Esq. 
 (b) if to Shareholder: 
 to the address set forth below the name of Shareholder on the signature page hereof. 
  

 6 

 with a copy to: 
 Fried, Frank, Harris, Shriver & Jacobson LLP 
 One New York Plaza 
 New York, New York 10004 
 Facsimile: +1 (212) 859-4000 
 Telephone: +1 (212) 859-8000 
 Attention: Philip Richter, Esq. 
                  Brian Mangino, Esq. 
 18.
Each Party the Drafter. This Agreement and the provisions contained herein shall not be construed or interpreted for or against any party to this Agreement because that party drafted or caused that party’s legal representative to draft
any of its provisions. 
 [Signature page follows] 
  

 7 

 IN WITNESS WHEREOF, the parties hereto have executed this Non-Competition Agreement as of the date first
above written. 
  

			
	FRESENIUS SE
		
	By:	 	/s/ Dr. U.M. Schneider
	Name:	 	Dr. U.M. Schneider
	Title:	 	President and CEO

			
		
	By:	 	/s/ St. Sturm
	Name:	 	St. Sturm
	Title:	 	CFO

  

			
	SHAREHOLDER
	
	/s/ Dr. Patrick Soon-Shiong
	Dr. Patrick Soon-Shiong
	Address:	 	 11755 Wilshire Blvd., Suite 2000
 Los Angeles, CA
90025

	Facsimile: +1 (310) 405-7588

 [Signature Page to Non-Competition Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00145-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00145-of-00352.parquet"}]]